C12-200 |
Catalog No.GC64081
One-Click Copy Product Info
|
C12-200 is an ionizable cationic lipidoid commonly utilized as a nucleic acid delivery vehicle.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1220890-25-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
C12-200 is an ionizable cationic lipidoid commonly utilized as a nucleic acid delivery vehicle[1]. C12-200 possesses unique ionization properties, enabling it to bind with negatively charged nucleic acid molecules, such as mRNA, under physiological conditions to form stable complexes. This facilitates efficient nucleic acid encapsulation and promotes cytosolic delivery, making it applicable in drug delivery, vaccine development, and gene therapy, particularly suited for mRNA vaccine delivery systems[2-4].
In vitro, pretreatment of rat dorsal root ganglion (DRG) neurons, rat primary cortical neurons, and the human cortical neuron cell line (HCN-2) with C12-200 lipid nanoparticles (LNPs) at 50nM for 4–24 hours significantly enhanced siRNA cellular uptake efficiency while maintaining high cell viability[5]. Co-incubation of ARPE-19 cells and MIO-M1 Müller glial cells with C12-200 LNPs (loaded with 1μg mRNA or 0.2–1μg saRNA) for 24 hours increased enhanced green fluorescent protein (eGFP) expression levels in the cells[6].
In vivo, administration of C12-200 LNPs (1mg mRNA/kg) via intraperitoneal or intravenous injection in 6-8-week-old female C57BL/6 mice significantly altered the biodistribution pattern of mRNA. Compared to the cholesterol-based benchmark LNP (S2), C12-200 LNPs exhibited strong liver tropism[7]. Additionally, intraperitoneal injection of C12-200 LNPs (1mg/kg siRNA-Cy5.5) in 8-12-week-old Balb/c mice significantly enhanced the uptake of Cy5.5-labeled siRNA in GATA6+ large peritoneal macrophages (LPMs) and induced the migration of LPMs to the lung tissue via systemic circulation within 12-24 hours following clodronate-mediated depletion of alveolar macrophages (AMs)[8].
References:
[1] Reinhart AG, Osterwald A, Ringler P, et al. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions. Mol Pharm. 2023 Dec 4;20(12):6492-6503.
[2] Barbieri BD, Peeler DJ, Samnuan K, et al. The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA. J Control Release. 2024 Oct;374:280-292.
[3] Kauffman KJ, Dorkin JR, Yang JH, et al. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015 Nov 11;15(11):7300-6.
[4] Labonia MCI, Estapé Senti M, et al. Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration. J Control Release. 2024 May;369:734-745.
[5] Khare P, Dave KM, Kamte YS, et al. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells. AAPS J. 2021 Dec 6;24(1):8.
[6] Li W, Vanluchene H, Raes L, et al. Efficacy versus immunogenicity of LNP-mediated delivery of mRNA and self-amplifying RNA upon intravitreal injection in the mouse eye. J Control Release. 2025 Sep 10;385:114027.
[7] Patel SK, Billingsley MM, Mukalel AJ, et al. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics. 2024 Jan 1;14(1):1-16.
[8] Oza D, Ivich F, Pace J, et al. Lipid nanoparticle encapsulated large peritoneal macrophages migrate to the lungs via the systemic circulation in a model of clodronate-mediated lung-resident macrophage depletion. Theranostics. 2024 Apr 8;14(6):2526-2543.
Preparation of siRNA-Loaded Liposomes
This protocol is provided as a guide only and should be modified according to your specific needs.
(1) Lipid/Ethanolic Phase Preparation: Dissolve the lipid components in ethanol at a molar ratio of 50/10/38.5/1.5 (C12-200 / DSPC / Cholesterol / PEG-DMG).
(2) Aqueous Phase Preparation: Prepare a 1mg/mL solution of siRNA in 10 mM citrate buffer, pH=4.0.
(3) siRNA Liposome Formation via Rapid Mixing: Under continuous vortexing, add the entire volume of the lipid/ethanolic phase to the aqueous phase dropwise over 30 seconds. Vortex the mixture for an additional 30 seconds. Add a pre-calculated volume of 1X PBS, pH 7.4, to the siRNA liposomes to adjust the final siRNA concentration to the desired level. Maintain the weight-to-weight (w/w) ratio of the ionizable cationic lipidoid (C12-200) to siRNA at 5:1.
Precautions:
(1) Maintain sterile techniques where applicable to prevent contamination.
(2) Store the prepared liposomes at 2-8°C when not in use. Monitor colloidal stability over time.
References:
[1] Khare P, Dave KM, Kamte YS, et al. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells. AAPS J. 2021 Dec 6;24(1):8.
| Cas No. | 1220890-25-4 | SDF | |
| Formula | C70H145N5O5 | M.Wt | 1136.93 |
| Solubility | DMSO : 100 mg/mL (87.96 mM; Need ultrasonic) | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 879.6 μL | 4.3978 mL | 8.7956 mL |
| 5 mM | 175.9 μL | 879.6 μL | 1.7591 mL |
| 10 mM | 88 μL | 439.8 μL | 879.6 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)